Drug Profile
CXS 876
Latest Information Update: 20 Jul 2007
Price :
$50
*
At a glance
- Originator ChemGenex Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action DNA repair enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Jun 2004 AGT Biosciences has merged with ChemGenex Therapeutics Inc to form ChemGenex Pharmaceuticals
- 15 Apr 2002 Preclinical trials in Cancer in the US (unspecified route)